The Glp-1 Analog Liraglutide Protects Against Angiotensin II and Pressure Overload-Induced Cardiac Hypertrophy via PI3K/Akt1 and AMPKa Signaling
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Glp-1 analog, liraglutide (Lir), have been shown to reduce infarct size and improve cardiac function after myocardial ischaemia in rodents with or without diabetes. But the effect of Lri on angiotensin II (AngII) and pressure overload induced cardiac remodelling in non-diabetic mice and the underlying mechanism is unclear. The aim of this study is to investigate the effect of Lir on cardiac remodeling induced by AngII infusion, and explore its possible mechanism. Mice subjected to Angiotensin II as well as thoracic aorta coarctation to induce cardiac remodelling model. Mice were daily injected with either liraglutide or saline for 2 weeks. Neonatal rat cardiomyocytes and human AC cell lines were stimulated with AngII to induced cardiomyocytes remodelling model. Both in vivo and in vitro experiments indicated Lir significantly inhibited cardiac hypertrophy and improved cardiac function through directly suppressing the activation of PI3K/Akt1 and stimulating AMPKα signaling pathways. Moreover, mTOR activator (MHY1485), overexpression of constitutively active Akt, and knockdown of AMPKa2 expression all can abolish the protective effects of Lri. Moreover, the protective effects of Lri in vivo was lost in AMPKa2 knockout mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 1×
“GLP1 and its analogs have also been demonstrated to exert cardioprotective actions in a few ischemia/reperfusion models (Ban et al., 2008; Noyan-Ashraf et al., 2009; Timmers et al., 2009).”
BackgroundNoyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575
Noyan-Ashraf, M. H., Shikatani, E. A., Schuiki, I., Mukovozov, I., Wu, J., Li, R.-K., Volchuk, A., Robinson, L. A., Billia, F., Drucker, D. J., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.091215 · Cited by 259
Self-citationPhysiological role of AMP-activated protein kinase (AMPK): insights from knockout mouse models
Viollet, B., Andreelli, F., Jørgensen, S. B., Perrin, C., Flamez, D., Mu, J., Wojtaszewski, J. F. P., Schuit, F. C., Birnbaum, M., Richter, E., et al. (2003) · Biochemical Society Transactions · doi:10.1042/bst0310216 · Cited by 241
Glucagon-like peptide-1 (GLP-1) action in the mouse area postrema neurons
Kawatani, M., Yamada, Y., & Kawatani, M. (2018) · Peptides · doi:10.1016/j.peptides.2018.07.010 · Cited by 32
Cited by
Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
Muzurović, E., & Mikhailidis, D. P. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1795132 · Cited by 35
Zhang, Y., Li, Y., Zhao, J., Wang, C., Deng, B., Zhang, Q., & Shi, C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.781856 · Cited by 15
Metadata
- Authors
- Li, R., Shan, Y., Gao, L., Wang, X., Wang, X., & Wang, F.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2019-06-05
- Volume
- 10
- Pages
- 537-537
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2969696158
- Cited by
- 46
- References
- 5
- FWCI
- 2.61
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Glp-1 Analog Liraglutide Protects Against Angiotensin II and Pressure Overload-Induced Cardiac Hypertrophy via PI3K/Akt1 and AMPKa Signaling. https://app.cochat.ai/papers/10.3389/fphar.2019.00537
- The paper
- Li, R., Shan, Y., Gao, L., Wang, X., Wang, X., & Wang, F. (2019). The Glp-1 Analog Liraglutide Protects Against Angiotensin II and Pressure Overload-Induced Cardiac Hypertrophy via PI3K/Akt1 and AMPKa Signaling. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2019.00537
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.